Nakajima H, Tochino Y, Fujino-Kurihara H, Yamada K, Gomi M, Tajima K, Kanaya T, Miyazaki A, Miyagawa J, Hanafusa T
Res Commun Chem Pathol Pharmacol. 1985 Nov;50(2):251-7.
Subcutaneous administration of monosodium glutamate (MSG) to neonatal female non-obese diabetic (NOD) mice resulted in obesity associated with stunting and hyperinsulinemia. However, the cumulative incidence of diabetes mellitus at 25 weeks of age in the MSG group was significantly lower than in the control group (10.3% vs. 43.6%, P less than 0.005). The immunoreactive insulin content of the pancreas from the 13- to 20-week-old MSG-treated mice was higher than that of the control mice (P less than 0.005). Immunohistochemistry showed that the number of pancreatic B-cells was well preserved and insulitis was attenuated in the MSG-treated mice. Plasma corticosterone and 3, 5, 3'-triiodothyronine levels were elevated in the MSG group. These results suggested that, by the MSG treatment, the B-cell functions were maintained through the modification of the degenerative process of the islets in the NOD mouse.
给新生雌性非肥胖糖尿病(NOD)小鼠皮下注射味精(MSG)会导致肥胖,并伴有发育迟缓及高胰岛素血症。然而,MSG组在25周龄时糖尿病的累积发病率显著低于对照组(10.3% 对43.6%,P<0.005)。13至20周龄经MSG处理的小鼠胰腺中免疫反应性胰岛素含量高于对照小鼠(P<0.005)。免疫组织化学显示,经MSG处理的小鼠胰腺B细胞数量保存良好,胰岛炎减轻。MSG组血浆皮质酮和3,5,3'-三碘甲状腺原氨酸水平升高。这些结果表明,通过MSG处理,NOD小鼠胰岛的退化过程得到改变,从而维持了B细胞功能。